Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 6/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.46 |
| ▸ | USP7 | Q93009 | 2/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321313 | 0.94 | KCNQ3 (0.48) | KCNQ3KCNQ2USP7CSNK1DKCNQ4 | |
| SCHEMBL1321502 | 0.91 | KCNQ3 (0.46) | KCNQ3KCNQ2USP7CSNK1DTRPA1 | |
| SCHEMBL1321730 | 0.90 | KCNQ3 (0.48) | KCNQ3KCNQ2USP7CSNK1DTRPA1 | |
| SCHEMBL1319870 | 0.88 | KCNQ3 (0.49) | KCNQ3KCNQ2USP7CSNK1DHPGD | |
| SCHEMBL1320942 | 0.87 | POLB (0.48) | KCNQ3KCNQ2USP7HPGD | |
| SCHEMBL1320937 | 0.86 | USP7 (0.46) | USP7 | |
| SCHEMBL1320250 | 0.86 | KCNQ3 (0.45) | KCNQ3KCNQ2USP7CSNK1DCSNK1E | |
| SCHEMBL1320161 | 0.86 | KCNQ3 (0.45) | KCNQ3KCNQ2USP7CSNK1DCSNK1E | |
| SCHEMBL1321283 | 0.85 | GABRA1 (0.46) | KCNQ3KCNQ2USP7HPGD | |
| SCHEMBL1321426 | 0.85 | GPR139 (0.40) | KCNQ3KCNQ2USP7MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | KCNQ3 29/4885KCNQ2 7/4885USP7 2505/4885 |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | KCNQ3 23/4885KCNQ2 7/4885USP7 2598/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | KCNQ3 23/4885KCNQ2 7/4885USP7 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.